Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection

Behavioral and Biomedical Research Department, Family Health International, Research Triangle Park, NC 27709, USA.
AIDS (London, England) (Impact Factor: 6.56). 02/2010; 24(4):573-82. DOI: 10.1097/QAD.0b013e32833433df
Source: PubMed

ABSTRACT High levels of HIV-1 viremia exist in peripheral blood during acute and early infection; however, data on HIV-1 viral loads in female genital secretions during this period are sparse.
Prospective cohort of 188 African women with primary HIV-1 infection.
HIV-uninfected and infected women were followed quarterly; we tested serial plasma specimens by HIV PCR to estimate infection dates. We used the Loess procedure to estimate the magnitude and timing of viral setpoints in plasma and cervical secretions and generalized estimating equations (GEE) to identify predictors of plasma and cervical viral setpoints.
We estimated the mean HIV-1 plasma setpoint to be 4.20 log10 HIV-1 RNA copies/ml [95% confidence interval (CI) 4.04-4.35] at 121 days (95% CI 91-137) from infection; an analogous mean cervical viral setpoint was 1.64 log10 HIV-1 RNA copies/swab (95% CI 1.46-1.82) at 174 days (95% CI 145-194) from infection. Cervical loads were significantly higher (0.7-1.1 log10 copies/swab) during acute infection than subsequently. Subtype D infection, pregnancy, breastfeeding, and older age at the time of infection were associated with higher plasma viral setpoint. Subtype C infection, nonviral sexually transmitted infections, having a partner spending nights away from home, recent unprotected sex, and shorter time since infection were associated with higher cervical HIV-1 loads. Hormonal contraception was not associated with either the HIV-1 plasma setpoint or cervical loads during early infection.
Cervical HIV-1 viral loads were highest during acute infection and then declined up to 6 months following infection, when a 'setpoint' was attained. The prognostic value of a cervical 'setpoint' on future transmission risk remains unclear.

Download full-text


Available from: Eric Arts, Aug 19, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute HIV infection (AHI), the earliest period after HIV acquisition, is only a few weeks in duration. In this brief period, the concentration of HIV in blood and genital secretions is extremely high, increasing the probability of HIV transmission. Although a substantial role of AHI in the sexual transmission of HIV is biologically plausible, the significance of AHI in the epidemiological spread of HIV remains uncertain. AHI is diagnosed by detecting viral RNA or antigen in the blood of persons who are HIV seronegative. Depending on the setting, persons with AHI represent between 1 and 10% of persons with newly diagnosed HIV infection. The high concentration of virus during AHI leads to increased infectiousness, possibly as much as 26 times greater than during chronic infection. In mathematical models, the estimated proportion of transmission attributed to AHI has varied considerably, depending on model structure, model parameters, and the population. Key determinants include the stage of the HIV epidemic and the sexual risk profile of the population. Despite its brief duration, AHI plays a disproportionate role in the sexual transmission of HIV infection. Detection of persons with AHI may provide an important opportunity for transmission prevention.
    Current opinion in HIV and AIDS 07/2010; 5(4):277-82. DOI:10.1097/COH.0b013e32833a0d3a · 4.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review will discuss the role of antiretroviral therapy to treat primary HIV infection (PHI) as a strategy to prevent onward viral transmission. Novel technology has greatly enhanced the appreciation of the characteristics of recently transmitted HIV-1 variants. Recent primate data demonstrate marked enhanced infectiousness of viral variants isolated from acutely infected macaques compared with viruses isolated from animals in the chronic phase of disease. These data are supported by phylogenetic analyses of recently transmitted cases in humans, implying that individuals with PHI may contribute disproportionately to onward transmission at a population level. In the absence of randomized clinical trial data supporting individual benefit of antiretroviral therapy, targeting and treating individuals with PHI as a public health intervention strategy represent a paradigm shift from current treatment strategies based around proven individual benefit alone. However, there is increasing evidence that PHI contributes disproportionately to viral transmission at a population level and failure to incorporate the potential role PHI plays, particularly in focused epidemics, maybe a naïve omission of many of the current mathematical models evaluating the impact of universal test and treat on population-level HIV incidence.
    Current opinion in HIV and AIDS 07/2010; 5(4):283-90. DOI:10.1097/COH.0b013e32833a6b11 · 4.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: High viral load (VL) setpoint is a marker for rapid HIV progression. Few studies have examined whether use of hormonal contraception (HC) prior to HIV seroconversion affects VL setpoint. We determined VL setpoints in 285 HIV seroconverters using blood samples collected 6 months or more after estimated HIV seroconversion but before disease progression to CD4 ≤ 250 or WHO Stage 3 or 4. We used multivariate linear regression to estimate the effect of HC use before HIV seroconversion on VL setpoint, and multivariate Cox regression to estimate the hazards ratio of death associated with VL setpoint. Of 285 women, 42 (15%) reported using HC before HIV seroconversion. Mean VL setpoint was 4.49 (SD 0.79) log10 copies per milliliter among women who used HC before HIV seroconversion and 4.47 (SD 0.86) among non-HC users (P = 0.88). In multivariate analysis, HC before HIV seroconversion was not associated with VL setpoint (+0.11 log10 copies/mL; P = 0.47). Higher socioeconomic status was associated with lower VL setpoint (-0.43 log10 copies/mL; P = 0.04). VL setpoints above the median were associated with faster time to death (adjHR: 2.54, 95% confidence interval: 1.30 to 4.98, P < 0.01). Use of HC before HIV seroconversion was not associated with elevated VL setpoint.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 11/2010; 56(2):125-30. DOI:10.1097/QAI.0b013e3181fbcc11 · 4.39 Impact Factor
Show more